Immunome Stock Buy Hold or Sell Recommendation
| IMNM Stock | USD 9.82 0.40 4.25% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Immunome is 'Strong Sell'. The recommendation algorithm takes into account all of Immunome's available fundamental, technical, and predictive indicators you will find on this site.
Check out Immunome Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide. Note, we conduct extensive research on individual companies such as Immunome and provide practical buy, sell, or hold advice based on investors' constraints. Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Immunome |
Execute Immunome Buy or Sell Advice
The Immunome recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immunome. Macroaxis does not own or have any residual interests in Immunome or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immunome's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Immunome Trading Alerts and Improvement Suggestions
| Immunome generated a negative expected return over the last 90 days | |
| Immunome has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 14.02 M. Net Loss for the year was (106.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunome currently holds about 34.65 M in cash with (7.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86. | |
| Immunome has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Immunome files to sell 1.80M shares of common stocks by selling shareholders |
Immunome current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunome analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunome analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Immunome Returns Distribution Density
The distribution of Immunome's historical returns is an attempt to chart the uncertainty of Immunome's future price movements. The chart of the probability distribution of Immunome daily returns describes the distribution of returns around its average expected value. We use Immunome price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immunome returns is essential to provide solid investment advice for Immunome.
| Mean Return | -0.52 | Value At Risk | -7.21 | Potential Upside | 5.97 | Standard Deviation | 4.01 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immunome historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Immunome Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Immunome, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Immunome back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 1.1 M | Vestal Point Capital Lp | 2024-06-30 | 1000 K | Woodline Partners Lp | 2024-06-30 | 922.9 K | Avidity Partners Management Lp | 2024-06-30 | 873.9 K | Brown Advisory Holdings Inc | 2024-09-30 | 860.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 743.9 K | Victory Capital Management Inc. | 2024-09-30 | 730.8 K | Tang Capital Management Llc | 2024-06-30 | 720 K | Sofinnova Ventures | 2024-06-30 | 655.7 K | T. Rowe Price Investment Management,inc. | 2024-09-30 | 5.8 M | Redmile Group, Llc | 2024-09-30 | 4.9 M |
Immunome Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (233K) | (586K) | (79K) | (248K) | (30.5M) | (29.0M) | |
| Change In Cash | 941K | 37.2M | 9.5M | (28.9M) | 78.4M | 82.3M | |
| Net Borrowings | (612K) | 49K | (113K) | 492K | 565.8K | 594.1K | |
| Free Cash Flow | (9.8M) | (12.7M) | (18.3M) | (28.9M) | (8.4M) | (8.8M) | |
| Other Non Cash Items | 3K | (2K) | 4K | 7.3M | 80.3M | 84.3M | |
| Capital Expenditures | 233K | 586K | 79K | 248K | 831K | 872.6K | |
| Net Income | (10.4M) | (17.8M) | (24.7M) | (36.9M) | (106.8M) | (101.5M) | |
| End Period Cash Flow | 2.6M | 39.9M | 49.3M | 20.4M | 98.8M | 103.7M | |
| Change To Netincome | 17K | 6.2M | 3.0M | 5.3M | 6.1M | 3.2M |
Immunome Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immunome or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immunome's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immunome stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.78 | |
β | Beta against Dow Jones | 2.12 | |
σ | Overall volatility | 3.94 | |
Ir | Information ratio | -0.16 |
Immunome Volatility Alert
Immunome exhibits very low volatility with skewness of 0.12 and kurtosis of 0.59. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunome's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunome's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Immunome Fundamentals Vs Peers
Comparing Immunome's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immunome's direct or indirect competition across all of the common fundamentals between Immunome and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immunome or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immunome's fundamental indicators could also be used in its relative valuation, which is a method of valuing Immunome by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Immunome to competition |
| Fundamentals | Immunome | Peer Average |
| Return On Equity | -2.76 | -0.31 |
| Return On Asset | -0.4 | -0.14 |
| Operating Margin | (15.06) % | (5.51) % |
| Current Valuation | 375.52 M | 16.62 B |
| Shares Outstanding | 62.42 M | 571.82 M |
| Shares Owned By Insiders | 16.77 % | 10.09 % |
| Shares Owned By Institutions | 83.47 % | 39.21 % |
| Number Of Shares Shorted | 10.47 M | 4.71 M |
| Price To Book | 2.74 X | 9.51 X |
| Price To Sales | 60.51 X | 11.42 X |
| Revenue | 14.02 M | 9.43 B |
| EBITDA | (28.27 M) | 3.9 B |
| Net Income | (106.81 M) | 570.98 M |
| Cash And Equivalents | 34.65 M | 2.7 B |
| Cash Per Share | 2.86 X | 5.01 X |
| Total Debt | 1.65 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 4.36 X | 2.16 X |
| Book Value Per Share | 4.97 X | 1.93 K |
| Cash Flow From Operations | (7.57 M) | 971.22 M |
| Short Ratio | 18.28 X | 4.00 X |
| Earnings Per Share | (7.94) X | 3.12 X |
| Target Price | 30.0 | |
| Number Of Employees | 55 | 18.84 K |
| Beta | 1.82 | -0.15 |
| Market Capitalization | 612.93 M | 19.03 B |
| Total Asset | 148.54 M | 29.47 B |
| Retained Earnings | (222.81 M) | 9.33 B |
| Working Capital | 122.87 M | 1.48 B |
| Net Asset | 148.54 M |
Note: Disposition of 14380 shares by Max Rosett of Immunome at 16.01 subject to Rule 16b-3 [view details]
Immunome Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Immunome . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Immunome Buy or Sell Advice
When is the right time to buy or sell Immunome? Buying financial instruments such as Immunome Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Immunome in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Moderate Funds Thematic Idea Now
Moderate Funds
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Immunome Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.